Index of Current Clinical Trials

 Listed below are study summaries of the clinical trials SDCRI is presently supporting. (Programs for prostate cancer and brain tumors are under development).

1. Breast Cancer
2. Colorectal Cancer
3. Low Grade Non-Hodgkin's Lymphoma
4. Non-Small Cell Lung Cancer (NSCLC)
5. Prostate Cancer

Colorectal Cancer

1. A Phase III Randomized Study Comparing Standard Chemotherapy Compared to Standard Chemotherapy with a Novel Agent

Target Patient Population
· Patients must have already received first line treatment for metastatic colon or rectal cancer
· Patients must have already received the drug Irinotecan (also called Camptosar or CPT-11)
· Patients must not have received more than 1 prior chemotherapy for the treatment of metastatic disease. Patients may have received treatment in the adjuvant setting as well.
· Patients must not have received the drug Oxaliplatin

All patients will receive standard chemotherapy for relapse after treatment for metastatic disease. Patients will be randomized to receive standard chemotherapy or standard chemotherapy plus a new novel agent. This is an open label study with a 1 to 1 randomization, therefore all patient will know which treatment group they have been assigned. The study medication is epidermal growth factor receptor blocker that is used in combination with chemotherapy.

Please contact Dawn Billingsley at 760-598-1700 for more details

2. An Open Label Trial Using the SALTZ regimen with a Growth Factor for Patients with Metastatic Disease

Target Populations
· Patients must have metastatic colorectal disease that can be measured either by Physical exam or CT scan.
· Patients must not have received the drug Irinotecan in the last 3 months
· Patients may have received any number or combination of previous treatments as long as they are eligible for treatment with the SALTZ regimen

All patients will receive standard chemotherapy according to the SALTZ regimen. All patients will receive the study medication (ie: growth factor) for 5 day following chemotherapy treatment. This is a non-randomized study, therefore all patient will receive the same treatment.

Please contact Christine DeFrancisco at 760-598-1700 for more details.

3. A Phase II Double-Blind Study Comapring a Standard Chemotherapy With or Without a Growth Factor

Target Populations
· Patients must have metastatic or locally advance colorectal disease that can be measured either by Physical exam or CT scan
· Patients must not have had chemotherapy for metastatic disease. Patients may have received 5-FU combinational chemotherapy in the adjuvant setting only

The patient will receive standard chemotherapy by continuous infusion with or without a novel growth factor. The study is a randomized, double-blind study, therefore the patient and the doctor will not know which group the patient has been assigned.

Please contact Dawn Billingsley at 760-598-1700 for more details.